Role of chemokines in T-cell acute lymphoblastic Leukemia: From pathogenesis to therapeutic options
International Immunopharmacology · 2023
DOI: 10.1016/j.intimp.2023.110396 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2023. Verfasst von YiFan Zhao und 6 weiteren Autor:innen. Beteiligte Einrichtung: First Center Clinic College of Tianjin Medical University, Tianjin 300192, China. Hauptthemen laut MEDLINE: Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 197 Literaturangaben. Gefördert von: Tianjin Medical University, National Natural Science Foundation of China.
Abstract (Originalsprache)
T-cell acute lymphoblastic leukemia (T-ALL) is a highly heterogeneous and aggressive subtype of hematologic malignancy, with limited therapeutic options due to the complexity of its pathogenesis. Although high-dose chemotherapy and allogeneic hematopoietic stem cell transplantation have improved outcomes for T-ALL patients, there remains an urgent need for novel treatments in cases of refractory or relapsed disease. Recent research has demonstrated the potential of targeted therapies aimed at specific molecular pathways to improve patient outcomes. Chemokine-related signals, both upstream and downstream, modulate the composition of distinct tumor microenvironments, thereby regulating a multitude of intricate cellular processes such as proliferation, migration, invasion and homing. Furthermore, the progress in research has made significant contributions to precision medicine by targeting chemokine-related pathways. This review article summarizes the crucial roles of chemokines and their receptors in T-ALL pathogenesis. Moreover, it explores the advantages and disadvantages of current and potential therapeutic options that target chemokine axes, including small molecule antagonists, monoclonal antibodies, and chimeric antigen receptor T-cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- First Center Clinic College of Tianjin Medical University, Tianjin 300192, China.
- School of Medicine, Nankai University, Tianjin 300192, China.
- Department of Hematology, Tianjin First Central Hospital, Tianjin 300192, China.
- Department of Hematology, Tianjin First Central Hospital, Tianjin 300192, China. Electronic address: mingfengzhao@sina.com.
Förderung
- Tianjin Medical University
- National Natural Science Foundation of China
Zitieren
APA
Zhao, Y., Guo, R., Cao, X., Zhang, Y., Sun, R., Lu, W., & Zhao, M. (2023). Role of chemokines in T-cell acute lymphoblastic Leukemia: From pathogenesis to therapeutic options. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.110396
Vancouver
Zhao Y, Guo R, Cao X, Zhang Y, Sun R, Lu W, et al. Role of chemokines in T-cell acute lymphoblastic Leukemia: From pathogenesis to therapeutic options. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.110396
BibTeX
@article{Zhao2023,
author = {Zhao, YiFan and Guo, RuiTing and Cao, XinPing and Zhang, Yi and Sun, Rui and Lu, WenYi and Zhao, MingFeng},
title = {Role of chemokines in T-cell acute lymphoblastic Leukemia: From pathogenesis to therapeutic options},
journal = {International Immunopharmacology},
year = {2023},
doi = {10.1016/j.intimp.2023.110396}
}
EUVIMED